retatrutide triple agonist gip glp-1 glucagon phase 2 obesity Eli Lilly's shows promising weight loss results in 3 trial Retatrutide for weight loss: Study

But the tirzepatide shortage was declared resolved in December 2024, and the semaglutide shortage was declared resolved in February 2025

Irritation at the injection site is the most common reaction

30 , e202402552 (2024)

Young at the Young Medical Spa

This is really alarming, said Rita Jew, a pharmacist and president of the Institute for Safe Medication Practices

no reproductive safety data exists Anyone unwilling to run baseline and follow-up bloodwork (fasting glucose, IGF-1, HbA1c) Common Mistakes That Make Side Effects Worse Titrating dose up in the first week instead of holding at a low starting dose for 2-4 weeks Injecting close to a large carbohydrate meal, which amplifies the acute glucose-insulin antagonism Stacking with a GHRP at full dose from day one instead of introducing one variable at a time Ignoring early tingling or grip weakness instead of treating it as an immediate dose-reduction signal Running continuously for months with no off period, increasing pituitary desensitization risk Sourcing from a vendor with no third-party testing